MediWound (NASDAQ:MDWD) Stock Rating Upgraded by StockNews.com

MediWound (NASDAQ:MDWDGet Free Report) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

Separately, HC Wainwright lifted their target price on shares of MediWound from $26.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, January 16th.

View Our Latest Stock Analysis on MDWD

MediWound Trading Down 0.2 %

Shares of NASDAQ:MDWD opened at $12.14 on Wednesday. The company has a 50 day moving average of $11.33 and a 200 day moving average of $9.63. The stock has a market cap of $111.81 million, a P/E ratio of -6.87 and a beta of 0.91. MediWound has a 12 month low of $7.10 and a 12 month high of $14.01.

MediWound (NASDAQ:MDWDGet Free Report) last issued its quarterly earnings data on Tuesday, November 21st. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.21. MediWound had a negative net margin of 49.79% and a negative return on equity of 44.32%. The company had revenue of $4.78 million during the quarter, compared to analysts’ expectations of $4.73 million. During the same quarter in the previous year, the company earned ($0.91) earnings per share. On average, equities analysts forecast that MediWound will post -0.81 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MediWound

A number of hedge funds have recently made changes to their positions in the business. Yelin Lapidot Holdings Management Ltd. bought a new stake in MediWound during the 3rd quarter valued at $917,000. Sargent Investment Group LLC raised its holdings in MediWound by 7.0% during the 4th quarter. Sargent Investment Group LLC now owns 109,194 shares of the biopharmaceutical company’s stock valued at $1,111,000 after buying an additional 7,125 shares during the last quarter. Silverberg Bernstein Capital Management LLC bought a new stake in MediWound during the 4th quarter valued at $803,000. Wells Fargo & Company MN increased its position in MediWound by 16.0% during the 2nd quarter. Wells Fargo & Company MN now owns 112,727 shares of the biopharmaceutical company’s stock valued at $1,202,000 after purchasing an additional 15,535 shares during the period. Finally, BlackRock Inc. increased its position in MediWound by 122.6% during the 2nd quarter. BlackRock Inc. now owns 15,238 shares of the biopharmaceutical company’s stock valued at $162,000 after purchasing an additional 8,392 shares during the period. 22.32% of the stock is currently owned by institutional investors.

About MediWound

(Get Free Report)

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

Further Reading

Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.